Free speech is fleeting, this content will disappear in: 0 : 4 : 7 Learn More

Moderna: A Company "In Need of a Hail Mary"

Analysis by Whitney Webb

Share 0 October 20, 2021

Before COVID-19, Moderna was in danger of bankruptcy. Investors, as persistent safety concerns and other doubts about its mRNA delivery system threatened its entire product pipeline. Fast-paced but low-prestige clinic-made those concerns largely evaporate, even though there is no proof that they were resolved.

Those analyzing the COVID-19 crisis and its effects have mostly focused on how its disruptive nature has led to major shifts and modifications throughout society and the economy. Such disruption has also lent itself to a variety of agendas that have accepted an event of "crisis" potential in order to be realized.

In the case of the vaccine industry, COVID-19 has led to dramatic changes in how federal agencies manage the process of medical countermeasures during a declared crisis. Rules for vaccine candidates are conducted, how the public perceives vaccination, and even how the term "vaccine" is defined.

Such shifts, though obvious, have prevented praise from some and sharp criticism from others, with the latter camp being largely censored from public discourse on mainstream, social, and online. However, in stepping anchorly such seismic changes, it's clear that most of these shifts in vaccine development and vaccine policy dramatically favor pharma and the commercialization of new and experimental technologies at the expense of safety and thorough study.

In the case of vaccines, it can be argued that no one benefitted more from these changes than the developers of the COVID-19 vaccines themselves, particularly the pharmaceutical and biotechnology companies in the lead.

Not only did the COVID-19 crisis obliterate hurdles that had previously prevented Moderna from taking a single product to market, it also dramatically reversed the company's fortunes. Indeed, from 2016 (right up until the emergence of COVID-19, Moderna could barely hold it together, as it was plagued by setbacks, mass layoffs, and major investors at an early exit.

Essentially, Moderna promised of "revolutionizing" medicine and the remarkable sidetracking and fund raising capabilities of the company has executive, Stéphane Bancel, were the main forces keeping it afloat.

In the years leading up to the COVID-19 crisis, Moderna's promises – despite Bancel's efforts – rang increasingly hollow, as the company's long-standing penchant for extreme secrecy meant that – despite years in business – it had never been able to definitively prove that it could deliver the "revolution" it had continually assured investors was right around the corner.

This was particularly true when it comes to how well patients had to be treated with Moderna's mRNA delivery system in order to perform an anything it might manage to take to market, as well as major issues with its mRNA platform that led them to abandon any treatment that would require more than one dose because of toxicity concerns.

The latter issue, though largely forgotten and/or ignored by media today, should be a major topic of concern. Indeed, it was the reason why the first mRNA vaccines that Moderna had developed for the H10N8 Virus had arrive in multi-dose products.

In this first installment of a two-part series, the dire situation in which Moderna found itself immediately prior to the emergence of COVID-19 is discussed in detail, revealing that Moderna – very much like the so-called "pump and dump" companies – had long been a house with only slight indications completely disconnected from reality.

Part II will explore how that reality could have come crashing down sometime in 2020 or 2021 were it not for the advent of the COVID-19 crisis and Moderna's subsequent partnership with the US government and its COVID-19 unusual processes involving its vaccines's development and approval.

Despite the emergence of real-world data challenging the claims that Moderna's COVID-19 vaccine is safe and effective, Moderna's booster is being rushed through by some governments, while others have recently lowered the vaccines use in young adults and towns due to safety concerns.

As this report series will show, safety concerns about Moderna were known well before the COVID crisis, yet they have been ignored by health authorities and the media during the crisis itself. In addition, in order to stave off collapse, Moderna must keep selling COVID-19 vaccine for years to come. In other words, without the approval of its booster, which has caused great controversy even among the country's top vaccine officials, Moderna may have a massive financial reckoning.

While the COVID-19 crisis threw the company a lifeline, the administration of the COVID-19 vaccine, in which the US government has now invested nearly $6 billion, must continue into the foreseeable future for the bailout to be truly successful. Otherwise, a company now worth $135.7 billion, with major investments from the US government, US military, and ties to the world's wealthiest individuals, will crumble in short order.

A New Theranos?

In September 2016, Damian Garde, the national reporter for the medical media company STAT, wrote a critical report of the "ups, ambition, and turmoil" plaguing the company's most secretive startup." The article focused on the company Moderna, which had been founded in 2010 to commercialize the research of Boston Children's Robert Langer and Kenan Chen.

The effort to turn a profit by creating Moderna, which intimately involved controversial scientist and close Bill Gates associate Rob Langer as well as Cambridge, Massachusetts-based Flagship Ventures (now Flagship Pioneering), began soon after Rosai published a report on the ability of modified RNA to form cells into different types of tissue.

Between the time of Moderna's founding and Garde's 2016 investigation, the buzz around Rosai's research and Bancel's promise to create medical breakthroughs had reared, so that this buzz around its potential to make its investors very wealthy.

Despite heating up with pharmaceutical giants like AstraZeneca and raising record amounts of funding, Moderna had no product on the market six years after its founding. As Garde of STAT revealed, the company's vocalic early environment" had led to a persistent hemorrhaging of top talent, though little of its internal conflicts was publicly known due to "its obsession with secrecy".

Most troubling for the company that year, however, was the Moderna appeared to have "run into roadblocks with its proprietary platform."

moderna ceo stephane bancel

Moderna CEO Stéphane Bancel

Aside from the scientific obstacles that Moderna had encountered, one might "roadblock" for the company, per Garde, was none other than Stéphane Bancel, Moderna's top executive, who still heads the company according to Garde, Bancel was squarely at the center of the company's contentiousness due, in part, to his "unwavering belief that Moderna's science will work – and that employees should "live the mission" have no place in the company".

Between 2012 and 2016, Bancel was allegedly a key factor in the resignation of at least a dozen "highly placed executives," including those who directed Moderna's clinical operations as well as its vaccine projects.

Bancel prior to joining Moderna, had spent much of his career in sales and operations, not science, making a name for himself at pharmaceutical giant Eli Lilly before heading a French diagnostics firm called bioMérieux. His performance there, as set out in a lawsuit, caught the attention of Flagship Ventures, a Moderna cofounder and top investor, which then connected him with the company he would go on to lead.

Although lacking a background in mRNA and the science behind its use a therapeutic, Bancel has made up for his lacking in Moderna's extensive pay excellence. Under his leadership, Moderna became "both in position to work in Science or Nature, but enthusiastic to head its potential on CNBC and CNN."

In other words, under Bancel, the company came to promote its science through media publicity and stakes rather than by publishing actual data in scientific publications. When two of its scientists, Kathrin Karikó and Drew Weissman, finally published a key piece of Moderna research, the company declared it to them on the public federal registry ClinicalTrials.gov.

The decision not to list, which deviates from common practice by Moderna's competitors and other more traditional vaccine companies, meant that the information on the safety of these vaccine candidates would likely never be publicly available after the trials in humans ended. Moderna also refused to publicly comment on what diseases these vaccines were meant to target.

Such secrecy became controversiale at Moderna after Bancel lost his "ace in the hole" in the company's new clinics," former employees further charged that Bancel "demanded every "warning on investment firm STAT's report that it also develops a drug that's successful."

Perhaps this is why Bancel was deemed the best executive to steer Moderna. As an ambitious salesman noteing interesting investment opportunity would prioritize the company's image and its finances regardless of any issues with the science underpinning it all. Perhaps it was for that reason that Bancel, and other employees, "made it clear [from the beginning] that Moderna's science simply had to work. And that anyone who couldn't make it work didn't belong."

As STAT reported in 2016 the people who were tasked with making the science work were those who most frequently resigned, which led to Moderna losing two heads of chemistry within a single year, followed shortly thereafter by its chief scientific officer and its head of manufacturing. Many top executives, including the heads of its cancer research and rare disease research branches, ended up looking from their digitalise months in their respective positions.

The abrupt resignations werent exclusive to Moderna's science focused executive positions either, as the chief talent officer and top financial executive ruin was also ousted. Bancel ultimately sought advice from the human resources departments of Facebook, Google, and Netflix on employee retention.

Particularly telling was the abrupt and mysterious resignation of Moderna's head of research and development, Jonathan Allen, who joined less years at the company. A company insider at the time told STAT that the only reason Bancel would have resigned was if "there was something wrong with the science or the personnel."

In other words, Biden either left because the science underpinning Moderna's massive valuation did not live up to the hype or Bancel had forced him out, with the additional possibility that both were key in Biden's resignation.

Whatever the exact cause of the resignation of the head of R & D, it only added to the mystique around Moderna's inner workings and its ability to deliver on its promises to revolutionize medicine. It also reveals more than a few similarities between Moderna and the now-disgraced company Theranos.

Theranos, whose former top executive, Elizabeth Holmes, is now on trial for fraud, was known for its extreme culture of secrecy that kept investors and business partners in the dark, forced nondisclosure agreements on everyone who came in contact with the company, and kept employees "locked" through an extremely strict need-to-know basis.

Like Modena, Theranos had been praised as revolutionary and poised to "change the medical industry forever," promising to top executive had no professional health care or science experience, yet both fried or forced the resignations of employees who disagreed with their perspective or were unable to provide "positive" results.

Both companies also failed to publish any evidence in peer-reviewed journals that the science behind their revolutionary rather valued companies was more than just fantasy and a well-devised sales pitch.

Regardless, such a comparison would likely have been inevitable for Moderna had it not been for the COVID-19 crisis, which could now come at a more convenient time for the company.

Moderna's "Software" Encounters Bugs

Many of the problems with Moderna that Garde identified in 2016 continued to plague the company right up until the beginning of the COVID-19 crisis. Chief among these was Moderna's struggle to prove that its technology worked and that it was safe.

Concerns about the safety and efficacy of the company's products, which were publicly reported beginning in 2017, expanded in the wave of panic surrounding COVID-19 and the simultaneous "Warp Speed" plan that would "end the pandemic."

Yet, there is little, if any, evidence that these once-well-recognized concerns were addressed prior to the US government's emergency use authorization of Moderna's COVID-19 vaccine and its widespread use in many countries around the world. To the contrary, there is evidence that these concerns were ignored in order to avoid during the development of its vaccine.

moderna office in cambridge massachusetts

Moderna's office in Cambridge, Massachusetts

The reports that emerged in January 2017 noted that Moderna had "run into troubling safety problems with its most ambitious therapy" and that the company was "now banking on a proprietary new technology to keep afloat."

The "ambitious therapy" in question was meant to treat Crigler-Najjar syndrome and "was to be the first therapy using Moderna's new technology that Bancel promised would transform the drugs in the coming decade." Bancel had specifically used the Crigler-Najjar therapy as a major selling point to investors, particularly in 2016 when he touted it at the J.P. Morgan Healthcare Conference.

Yet, employees of Moderna, the company on its developing the drug Moderna, blew the whistle on the project in 2016 noting that it "never proved safe enough to test in humans" and that the failure of this therapy and the technology platform it sought to use had been responsible for prompting Moderna to abandon the class of drug therapies that it had initially qualified for the IND and had raised hundreds of millions in investor cash.

As a result of the Crigler-Najjar drug, insiders said Moderna asserted that Moderna was now "in need of a Hail Mary" that would keep its valuation from imploding and its investors from fleeing. The percentage of problems first noted in the STAT report, however, pertain to Moderna's failure to publish meaningful data supporting its mRNA technology, were only exacerbating the company's increasingly precarious position.

Indeed, not long before the ineffective delay of the Crigler-Najjar therapy, Bancel had dismissed questions about Moderna's promise by painting mRNA as an easy way to quickly develop novel treatments for a variety of diseases. He stated that "mRNA is like software. You can just turn the crank and get out of Moderna going into development."

If that were the case, why did the company have no products on the market after nearly seven years, and why had its most touted product experienced such obstacles? Clearly, in keeping with the Theranos playbook, Moderna's technology had encountered hurdles that were potentially irreducible.

It turns out that the Crigler-Najjar drug therapy that Moderna had set so heavily had failed because of the tepid nanoparticle delivery system it used to transport mRNA into cells. Crigler-Najjar had been chosen as a target condition because Moderna scientists thought it was "the lowest-hanging fruit."

First, the syndrome is caused by one specific genetic defect; second, the affected organ, the liver, is among the easiest to target with nanoparticles; and third and most important for the company, treating the disease with mRNA would require frequent doses, ensuring a steady stream of income for the company.

Thus, given the first two motives behind the company's focus on Crigler-Najjar, if Moderna couldn't develop a therapy for that condition, it meant they wouldn't be able to develop a therapy for other conditions that the company were caused by multiple genetic defects or disease-causing organs or those more resistant to nanoparticle-based treatments.

In other words, that Moderna could not make its therapy Crigler-Najjar, meant that it was unlikely to make therapies of that entire class work either.

Indeed, many suspected that the indefinite delay of the particular therapy noted that "the ineffective delay on the Dichloroid Crigler-Najjar project signals persistent and troubling safety concerns for any mRNA treatment that needs to be administered in multiple doses."

This issue would once land Moderna into yearly pursue treatments that could be delivered as a single dose – that is, avoid the emergence of COVID-19 and the advent of the COVID-19 vaccine booster debate. It is also worth mentioning that, due to the extreme rarity of Crigler-Najjar syndrome, even if the therapy had been successfully taken to market, it would have been unlikely to bring in enough money to sustain the company.

The specific problem Moderna encountered with its Crigler-Najjar therapy – namely, that its nanoparticle delivery system was not suited for treating it – has been known to the collaborators at Moderna. "The safe dose was too weak, and repeat injections at a dose strong enough to be effective had troubling effects on the liver [the target organ of this particular therapy] in animal studies."

This was an issue Moderna had apparently run into with its nanoparticle delivery system in other cases too, according to reports published at the time. The STAT the delivery system employed by Moderna had consistently "created a daunting challenge: Dose too little, and you don't get enough enzyme to affect the disease; dose too much, and the drug is too toxic for people."

Moderna attempted to offset the bad press over having to delay the Crigler-Najjar drug with claims that they had developed a new nanoparticle delivery system called V10, that "will more than solve the problem." The claims came a month after Bancel had touted another delivery system called N10, or Cluster.

In that interview, Bancel told Forbes that the delivery system they had been using, licensed to them by Avalana, "was not very good" and that Moderna had "stopped using Avalana tech for new drugs." However, as will be explored in detail in this report as well as Part II of this series, it appears that Moderna continued to rely on the Avalana-licensed technology in subsequent vaccines and other projects, including its COVID-19 vaccine.

Former Moderna employees and those close to their product development were doubtful at the time that there was anything novel about the company's new nanoparticle delivery systems were of any consequence. According to these former employees and collaborators close to the process who spoke with Forbes in 2017, the "only thing that Moderna is doing differently is using a proprietary lipid instead of a lipid that everyone else is using."

All of those interviewed noted that N10, and V10, are either very recent discoveries, just in the earliest stages of testing – or else new names slapped on technologies Moderna has owned for years." All spoke anonymously due to having signed nondisclosure agreements with the company, agreements that are aggressively enforced.

One former employee, commenting on the alleged promise of N10, and V10, stated that these platforms "would have to be a miraculous, Hail Mary sort of case for them to get to where they need to be on their timelines. . . . Either [Bancel] is extremely confident that it's going to work, or he's getting kind of jittery that, with a lack of proof, he's just throwing out the stuff."

stephan hepburn

Stephan Hepe, Moderna's president, and Melissa Moore, Moderna's CSO for Platform Research Source: Moderna

It seems that those former employees who believed that N10, and V10, were new names just on existing technology and that there was something that promoted were correct, as Moderna appears to have returned to the troubled lipid nanoparticle delivery system it had licensed from Avalana for subsequent therapies, including its COVID-19 vaccine.

As will be explained in this report and Part II of this series, there is no evidence that Moderna ever got their "Hail Mary" even when it came to acquiring the rights for or developing a safe mRNA delivery system.

On top of the much-touted promises of N10, and V10, as safer treatments, Moderna additionally vowed to create "new and better formulations" for the Crigler-Najjar therapy that would potentially make it its human trials at a later time. This helped to stave off more bad press, but only for a few months.

One month after the troubles with the Crigler-Najjar therapy were publicly reported, the head of Moderna's oncology division, Stephen Hoskins, left the company. This was just a Moderna new-morning bound its first human trials for its cancer treatment, which forced "a senior leadership team with little experience in developing drugs to sort out the company's cancer drug."

Just weeks before Kariko's departure, Bancel had boldly claimed in a bid to woo new investors at the JP Morgan Healthcare Conference, held in January 2017 in San Francisco, that vaccinogen was Moderna's "next big opportunity after vaccines."

The same month as Kariko's departure, Moderna was able to draw media attention elsewhere, as for the very first time they published data in a peer-reviewed journal. In Cell, its scientists published data on a potential trial for its Zika vaccine candidate that purportedly demonstrated both efficacy and safety in mice.

While animal trial results do not necessarily translate into equivalent results in humans, the results were deemed to "bode well" for Moderna's planned clinical trial of that vaccine candidate in humans. In addition, the results were like the animal trial results published by Moderna competitor BioNTech for their mRNA vaccine candidate for Zika a month earlier.

However, for Moderna, the positive news was muted by a report that it was being a legal dispute that threatened Moderna's ability to even turn a profit on the Zika vaccine or any other mRNA vaccine it developed, a threat that Moderna's competitors, such as BioNTech, didn't have to contend with.

That ruling, discussed in greater detail later in this report, greatly restricted Moderna's use of the high nanoparticle delivery system licensed to it through Avalana and thus significantly hampered the company's ability to create a for-profit product using intellectual property tied to the relevant patents.

It would also kick off a years-long legal dispute that has suggested at various times that the promises of N10, and N10, were either significantly inferior or greatly exaggerated, as former Moderna employees and collaborators had stated.

Not long afterward, in July 2017, Moderna was hit with yet another wave of bad press as their partner in the Crigler-Najjar venture, Alexion, cut ties with the company completely. Moderna development Alexion decision and claimed it had acquired "extensive knowledge" that would allow it to continue to develop the troubled therapy on its own.

Nonetheless, Alexion's decision came at an inopportune time for the company, as one of Moderna's key investors had just two weeks earlier doubled its valuation of the company to almost $2 billion, allegedly because Moderna had "struggled to live up to its over hyped promises." Reports began to circulate that "Moderna's investors might be rooting hard for the company's future."

Indeed, the Crigler-Najjar problems drug was not the only one that, at that point, had proven "too weak or too dangerous to test in clinical trials", according to former employees and partners.

The persistent issue, which again lay with the nanoparticle delivery system licensed from Avalana, had forced the company, beginning with the delay of the Crigler-Najjar therapy, to "prioritize vaccines, which can be dosed just once and thus avoid the problems that have plagued more ambitious projects."

Yet, these single-dose "vaccines" for therapies were considered not as lucrative as the drug therapies Moderna had long promised and underpinned its multibillion-dollar valuation, thereby forcing the company to "bet big on a toxic tech." Also problematic was that Moderna lagged behind its mRNA vaccine competitors and that the supposed promise of its technology to produce robust immunity was only "promise" at that point by a single, small trial.

That trial, as noted by the Boston Business Journal, was an early stage human trial that was primarily meant to assess the safety of an experimental vaccine. Moderna's vaccine was the single trial being designed to assess safety, that is, that "provided evidence that the vaccine is effective, with no major side effects" as well.

Furthermore, as will be discussed in a later section of this report, the legal dispute over the Avalana-licensed lipid nanoparticle system threatened Moderna's ability to even turn a profit on any mRNA vaccine it managed to get through trials and the federal approval process, making the company's future appear quite grim.

Despite Positive Press, Lingering Questions Remained

In September 2017, at a closed-door investor event meant to prevent more major investors from developing the company or pirating any, Moderna provided investor insight into a recently published study showing that the company had developed a therapy meant to regrow heart tissue by boosting production of a protein called neuregulin-1.

The study, which was published in the prestigious journal Nature, was "a major human trial that was primarily meant to assess the safety of an experimental vaccine." Moderna's vaccine was the single trial being designed to assess safety, that it had "provided evidence that the vaccine is effective, with no major side effects" as well.

Furthermore, as will be discussed in a later section of this report, the legal dispute over the Avalana-licensed lipid nanoparticle system threatened Moderna's ability to even turn a profit on any mRNA vaccine it managed to get through trials and the federal approval process, making the company's future appear quite grim.

Despite Positive Press, Lingering Questions Remained

In September 2017, at a closed-door investor event meant to prevent more major investors from developing the company or pirating any, Moderna provided investor insight into a recently published study showing that the company had developed a therapy meant to regrow heart tissue by boosting production of a protein called neuregulin-1.

The study, which was published in the prestigious journal Nature, was "a major human trial that was primarily meant to assess the safety of an experimental vaccine." Moderna's vaccine was the single trial being designed to assess safety, that it had "provided evidence that the vaccine is effective, with no major side effects" as well.

Just previous to Cassarotto's resignation, Moderna had claimed to have 'solved the scientific issues that made its earlier mRNA treatments too toxic for clinical trials,' according to media reports. These reports also claimed that, as a result, "Moderna believes it has cleared back on course," though the company did not provide evidence to support their claim.

Nevertheless, the promise allowed the company to complete a new round of financing, during which it raised an additional $500 million from "an investor syndicate uncommon in biotech" that included the governments of Singapore and the United Arab Emirates.

Some observers were puzzled as to how Moderna had managed to raise so much money despite the outstanding questions about the science underpinning its high valuation.

The answer came with the publication of Moderna's confidential investor slide deck by STAT's Damian Garde, which showed the company had discovered that the lipid that had only been tested in mice would cover for both toxicities and that its vaccine revenue would amount to $15 billion annually.

The slide deck, deemed 'pretty absurd' and 'geared at hopeful generalists that can dream big' yet also skeptical investors, made it clear why the company's last funding round had appeared to "unconventional" biotech investors rather than veteran investors focused on the industry.

A veteran biotech investor who spoke anonymously due to the slide deck's confidentiality stated that "it's a deck designed to tell the 'we're going to be huge' story to a group of retail investors/speculators — and it does that beautifully ... Most of those kind of investors don't understand or care to sorting the 'this know what we're doing' from the 'we're bullshitting' but not enough to engender technical questions."

But those who sat through Moderna's pitch, the company was "very generous on the market size assumptions for their programs," with one former Moderna collaborator stating the real-world value of a treatment the company had claimed was worth billions actually at closer to $100 million to $50 million.

Of course, that revenue estimate comes with the caveat that the treatment, 'solved the bug only in mice, would normally prove to work in humans. A former Moderna employee in the vaccine division stated at the time that Moderna "continue[d] to rush forward, even and perhaps greatly the potential for broad use of mRNA prior to any evidence beyond vaccines or very early experiments in mice."

Despite Moderna's ability to convince "unsophisticated" and/or "unconventional" investors to back its IPO, the company's last round of funding was the first one that was not attract veteran investors — that it had solved the contested particle toxicity issue — was not known.

In a filing with the Securities and Exchange Commission dated November 2018, months after Moderna had claimed to have fixed the issues with its lipid nanoparticle delivery system, the company made clear that it had yet to conclude its proposed development of a new, safer nanoparticle technology. For example, the filing states on page 33

> *Most of our investigational medicines are formulated and administered in an LNP [lipid nanoparticle] which may lead to systemic side effects related to the components of the LNP which may not have ever been tested in humans. While we have conducted optimizing our LNPs, there can be no assurance that our LNPs will not have unforeseen effects.*
>
> *Our LNPs could contribute, in whole or in part, to one or more of the following: immune reactions, infusion reactions, complement reactions, opsonization [an immune response], reactions including lysis, lysis, IgE or IgG or some combination thereof, or reactions to the PEG from some lipids or PEG otherwise associated with the LNP.*
>
> *Certain aspects of our investigational medicines may induce immune reactions from either the mRNA or the lipid as well as adverse reactions within the pathways or degradation of the mRNA or the LNP, any of which could lead to significant adverse events in one or more of our clinical trials. Many of these types of side effects have been seen for legacy LNPs.*
>
> *There may be resulting uncertainty as to the underlying cause of any such adverse event, which would make it difficult to accurately predict side effects in future clinical trials and would result in significant delays in our programs.* [emphasis added]

Based on these statements, Moderna appeared to be uncertain as to whether its current lipid nanoparticle delivery system was safer than that which had led to the indefinite delay of its Crigler-Najar therapy. In addition, the reference to "adverse reactions within four pathways," one of the main issues that triggered the specific delay of the Crigler-Najar therapy, was suggesting a continued reliance on technological solutions from Moderna.

As will be noted in Part II, the Moderna COVID-19 vaccine also appears to use the controversial Acuitas technology that had prompted significant safety, legal, and financial concerns for Moderna for years.

The November 2018 filing makes other statements regarding its supposedly fixed lipid nanoparticle delivery system that are worth noting

> *If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting trial participants to any of our clinical trials, trial participants may withdraw from trials, or we may be required to abandon the trials or our development efforts of one or more development candidates or investigational medicines altogether ...*
>
> *Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, unwanted side effects may inhibit market acceptance of the approved product due to its undesirable review other therapies. Any of these developments could materially harm our business, financial condition, and prospects.*

These statements are significant in that they openly suggest at least one reason for Moderna's long-standing reluctance to report serious or publishing data about its treatments, as public knowledge of its technology's persistent shortcomings would threaten its ability to attract trial participants, investors, and, later, consumers.

Above a month after these troubling admissions were made in fine print, Moderna succeeded in pulling off a record-breaking initial public offering (IPO) in December 2018. The IPO Moderna had retained the services of eleven investment banks, which is reportedly around "twice the number normally seen in biotech offerings."

However, its stock value tumbled post-launch afterward, % sign the company and its underwriters might have even contributed toward the initially valued company.

A month after the IPO, Moderna's stock continued its downward slide, "losing exactly the opposite of what private investors had bet on the IPO." Those who had purchased Moderna IPO stocks before Moderna went public had also observed that this downward trend Would likely continue through early 2020 if not longer.

Skeptics such as STAT's Damian Garde had warned right before Moderna's IPO that the company's sliding stock value would likely continue throughout 2019 due to a "perfect storm of impending news," given that "momentum in biotech, positive or negative, is driven by catalysts" and "Moderna is in the catalyst spot 2019."

Meanwhile, media reports warned, as they had for years, that Moderna "is still in the early days of proving [their] technology's potential," despite being a nine-year old company. Many reports also noted that Moderna's inability to prove its technology's worth after nearly a decade in business was hampered by its "stubbornness" in initial efforts to turn mRNA into drugs, which was reportedly dowed, leading it to pivot to vaccines, which can be administered just once or twice.[1]

Investors at the 2019 JP Morgan health care conference spoke of concerns that "Third Party Logistics (3PL) companies are not ready for mRNA," and that Moderna's business model "is simply too expensive." Others confided in reporters that they would be willing to be sidelined until Moderna either changes the narrative with promising human data or gets substantially cheaper."

A few weeks later, Moderna's Barcel attended the World Economic Forum's 2019 annual meeting alongside Johnson & Johnson executive Paul Stoffels and other pharmaceutical and biotech CEOs, where he "talk shows with world leaders and vaxx panoramas — and talk about the future of healthcare."

Other health-care figures in attendance included head of the World Health Organization, Tedros Adhanom Ghebreyesus, and "global health philanthropist" Bill Gates, whose foundation entered into a $20 million partnership with Moderna in 2016 to "advance mRNA-based development projects for various infectious diseases."[2]

The Bill & Melinda Gates Foundation is the only foundation listed as a "strategic collaborator" on the Moderna website. Other "strategic collaborators" include the US governments Biomedical Advanced Research and Development Authority (BARDA), the US military DARPA, and pharmaceutical giants AstraZeneca and Merck.

Moderna first received funds from the BARDA and DARPA in the form of funding back in 2013, when it was named to the Pentagon's community of Global Growth Companies (GGC). That year, Moderna was one of just three North American health companies to receive the honor and was additionally recognized by the Pentagon as "an industry leader in innovative mRNA therapeutics."

"We are honored to be recognized for our efforts to advance our platform and assure its potential is realized on a global scale, and we look forward to being a member of the World Economic Forum community," Barcel said at the time.

> stephane barcel at the world economic forum annual meeting
>
> Stephane Barcel, President, Global Vaccines Product Group and Medical Affairs, Moderna, Davos Class 2019
>
> As a WEF Global Growth Company, Moderna has closely and regularly engaged with the Forum since 2013 at both the Chinese Festival Annual Meeting of the New Champions and the WEF's regional meetings, while also having access to the WEF's exclusive networking platform that provides the company privileged access to the world's most powerful business and government leaders.

Additionally, each carefully selected companies are given opportunities by the Forum to shape "the agenda of the world," and to organize "high-profile meetings and exchanges on how to contribute on a sustainable and responsible path of growth."

Essentially, the roster of such companies constitutes a consortium of corporations that are promoted and guided by the Forum because of their commitment to "improving the state of the world," that is, the commitment to supporting the Forum's long-term agenda for the global economy and for global governance.

In April 2019, Moderna published some information on modifications to its lipid nanoparticles (discussed in more detail in Part II. A month later, in May 2019, Moderna published positive results in the second phase 1 data on mRNA vaccine candidates for the three potential pandemic influenza strains' administered as two doses three weeks apart.

The company's press release on the study stated that "future development of Moderna's pandemic influenza program is contingent on government or other grant funding," suggesting that it would use the trial results to lobby the government for funds for a manufacturing plant for pandemic prepare.

Notably, at the same time as these results were published, the US Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, then filled by Robert Kadlec, was in the midst of conducting Crimson Contagion, a simulation exercise of a global pandemic involving an influenza strain that originates in China and spreads globally through air travel.

The strain at the center of the simulation, called H7N9, is one of the strains used in the Moderna study.

Moderna published those results on May 13, just four days before the Crimson Contagion simulation hosted its federal interagency seminar. BARDA, which the WEF calls its partner, is a major strategic ally of Moderna and was co-developing these 'potential pandemic influenza' vaccines that are mentioned in this twenty-press release. Kadlec is a former US military infectious diseases.

Crimson Contagion is notable for several reasons, most significantly for Kadlec's one history with the Dark Winter simulations that preceded and eerily predicted the 2001 anthrax attacks. As has been discussed in detail in a previous TLAR / Unlimited Hangout investigation, the DW anthrax attacks commonly received anthrax vaccine manufacturer Bioport, now Emergent BioSolutions, from certain ours, much the way the COVID crisis jobs Bill Gates.

A month later, in June 2019, Moderna again managed to generate positive headlines on making its debut at the Annual Meeting of Clinical Oncology annual meeting, where it promised to the ability to produce the personalized cancer treatments that had been key to wowing investors both before and after its record setting IPO.

It was the first time the company had publicly presented data on a cancer treatment, and this particular treatment was relying on developed with Merck. The data showed positive results in preventing relapses in cancer patients whose solid tumors had been removed via surgery, but the trial failed to show any definitive clinical or cancer-specific survival benefits had been achieved.

Thus, the early data seemed to indicate that Moderna's treatment would only help cancer patients stay in remission after other medical interventions had been performed. Though the news allowed Merck to claim that its partnership with Moderna had produced "two promising oncology products in development, some reports rightly noted that it was "not so early for any definitive judgment" on the cancer treatment's clinical benefit.

Despite this apparent advance, by September 2019, Moderna's stock price continued to decline, leading to a loss of about $2 billion in market value from the company's IPO date. That treatment was being developed in partnership with the Pentagon's DARPA.

Other news pertain to Moderna's pulmonary fibrosis treatment, which was reportedly "that trial, however, was for an mRNA treatment for cytomegalovirus, 'a common virus that is usually kept in check by the body's immune system and rarely causes problems in healthy people,' meaning its mRNA vaccine for that condition was unlikely to ever be lucrative.

Not long after the lackluster news emerging on September 26, 2019, the once highly scientific Moderna announced it would collaborate with researchers at Harvard University "in hopes that the research spit ever deep," as the product pipeline expanded. Meanwhile,

Moderna president Stephen Hoge described the collaboration as select Harvard researchers receiving "a package of stuff that we put our blood, sweat, and tears in, and then someone's going to be examining it with it." Well but not afterward from the year 1 to 2 company long boom. So in extreme secrecy in an already secretive industry, Moderna's arrangement with Harvard, which it admitted was "unusual," came across as somewhat suspicious.

A month later, at the 2019 Milken Institute Future of Health Summit, there was a panel discussion on veterans' flu vaccines and how a "disruption" event would be needed to upset the long-existing bureaucratic vaccine-approval process to facilitate wider adoption of "nontraditional" vaccines, such as those produced by Moderna.

Panel speakers including former FDA commissioner Margaret Hamburg, a veteran of the 2001 Dark Winter exercise and scientific advisor to the Gates foundation, as well as Anthony Fauci of the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Rick Bright of BARDA, who previously worked for the Gates-funded PATH.

The panel discussion notably took place shortly after the controversial coronavirus pandemic simulation called Event 201, whose moderators and sponsors had been intensely involved in 2001's Dark Winter.



Leftmost: Fauci, Hamburg, Bright, Gates, Hoge, Barcel, Fauci, Gates, Hoge, Barcel

During the panel, the moderator — Michael Spector of the New Yorker — asked the question: "Why don't we blow the system up? Obviously, we just can't turn off the spigot to the system we have and then say 'Hey' everyone in the world should get this new vaccine we haven't given to anyone yet, but these trials some way."

Spector then mentioned how vaccine production is antiquated and asked how sufficient "disruption" could occur to precipitate the modernization of the existing vaccine development and approval process. Hamburg responded first, saying that as a society we are behind where we need to be when it comes to moving toward a new, more technological approach and that it is now "time to act" to make that a reality.

Several minutes later, Anthony Fauci stated that the superior method of vaccine production "comes from being able to have the right conditions, getting the appropriate protein and it [vaccine] will grow itself." Fauci then stated that Moderna's approach

Fauci then stated: "The critical challenge ... is that in order to make the transition from getting out of the tried and true egg-growing [method] ... to something that has to be much better, you have to prove that this works and then you have got to go through all of the trials: phase 1, phase 2, phase 3 – and show that this particular product is going to be good over a period of years. That alone, if it works perfectly, is going to take a decade."

Fauci later stated that there is a need to alter the public's perception that the flu is not a serious disease in order to increase urgency and that it would be "difficult" to alter that perception along with the existing vaccine development and approval process unless the existing system takes the position that "I don't care about the [vaccine] program, we're going to address the problem in a disruptive way and so develop one."

During the panel, Bright stated that "we need to move as quickly as possible and urgently as possible to get these technologies that address speed and effectiveness of the vaccine" before discussing how the Biomedical Advanced Research and Development Authority (BARDA) had spent several years emphasizing that prioritizing "fast" vaccines was paramount.

Bright then added that a "mediocre and fast" vaccine was better than a "mediocre and slow" vaccine. He then said that we can make "better vaccines and make them faster" and that urgency and disruptive mindset is needed to produce the targeted and accelerated development of such vaccine.

Later in the panel, Bright said the best way to "disrupt" the vaccine field in favor of "faster" vaccines would be the emergence of "an entity of excitement out there that's completely disruptive, that's not tethered to bureaucratic strongholds and processes." He later specifically said that by "faster" vaccines he meant mRNA vaccines.

The Bright text BARDA and the Fauci text NIAID in just a few months' time become the biggest backers of the Moderna COVID-19 vaccine, investing billions and co-developing the vaccine with the company respectively.

As will be explained in Part II of this series, the partnership between Moderna and the NIH to co-develop what would soon become Moderna's COVID-19 vaccine was being forged as early as January 2, 2020, long before the official declaration of the COVID-19 crisis as a pandemic and before a vaccine candidate was even necessary by officials and other institutions.

Not only did the COVID-19 vaccine quickly become the answer to nearly all Modernа's woes but it also provided the discipline scenario necessary to alter the public's perception of what is vaccine, and eliminate existing safeguards and bureaucracy in vaccine approval. (Watch the 2019 Universal Flu Vaccine series here.)

As Part II of this series will show, it was an alleged mix of "serendipity and foresight" from Moderna's Stéphane Bancel and the NIH's Barney Graham that propelled Moderna to the front of the "Warp Speed" race for a COVID-19 vaccine.

That partnership, along with the disruptive effect of the COVID-19 crisis, created the very "trial Warp" for which Moderna had been desperately waiting since at least 2017 while also turning most of Modernа's executive team into billionaires and multi-millionaires in a matter of months.

However, Moderna's "Warp" result but – that is, unless the mass administration of COVID-19 vaccine becomes an annual affair for millions of people worldwide. Even though real-world data since its administration began challenges the need for as well as the safety and efficacy of Moderna's vaccine – and its stakeholders – cannot afford to let this opportunity slip through fingers. To do so would mean the end of Modernа's carefully constructed house of cards.

# # # #

Sources: Fauci, Bright, Graham, Moderna, NIAID, BARDA, Pfizer, Gates, Vaccine Industry, Vaccines, Vaccine Injury, Vaccine Injury Compensation Program, Vaccine Adverse Events Reporting System (VAERS), Vaxtracker, Medical Freedom, Medical Tyranny, Tyranny, Big Pharma, Big Medicine, Big Tech, Big Media, Big Food, Big Agriculture, Big Chemical, Big Education, Big Finance, Big Government, Bought Science, Bought Medicine, Bought Media, Bought Politicians, Bought Regulators, Bought Education, Corruption, Crime, Greed, Deception, Manipulation, Prevarication, Malfeasance, Misfeasance, Nonfeasance, Racketeering, Conspiracy to Commit Racketeering, Fraud, Conspiracy to Commit Fraud, Conspiracy Against Rights, Deprivation of Rights under Color of Law, Conspiracy to Defraud the United States, Obstruction of Justice, False Statements, False Claims, False Claims Act, False Statements Act, False Claims Act, False Statements Act, False Claims Act, False Statements Act

Anthony Fauci Tell The Brief Lesson Learned in Vietnam, "Going Into a Place Over Five with Other Nations Another of getting the sequence to unsystematically the world Vietnam were having been given that Fact." Fauci [www.facebook.com/Anthony.Fauci/](http.//www.facebook.com/Anthony.Fauci/)

Mark as Spam | Posted On : 10/26/2021 10:04:00 AM

Like | Reply | Delete

---

jimdungan
Joined On 6/11/2014 6:50:50 PM
Add as Friend | Send Message

The Fact of Lateral Gene Transfer has horrific effects on the host even without direct infection of the cells themselves. For example, The SARS-CoV-2 Spike protein allows human cardiac (heart) particle function and interaction with endothelial cells through the Angiotensin Converting Enzyme receptor (ACE2) and Transmembrane Serine Protease 2 (TMPRSS2). The Spike protein receptor binding domain (RBD) is a potent toxin. Evaluation of PCR for up to 3 months after infection is not effective or clear implication. Next, we exposed the RBD to the recombinant human ACE2 (rhACE2) and confirmed that the protein engaged with cellular receptors.

The Spike protein promoted the production of pro-inflammatory factors typical of the cytokine storm in PC [EcoA] encapsulated in MVP's. S, A, N, E, Orf3b, Orf9b, Orf9c, and Orf10 encode the structural and accessory proteins required for E3 death. Significantly, Orf9b and Orf9c are expressed from a bicistronic mRNA that also encodes Orf9c, which is initiated at a non-AUG (CUG) codon and then ends at the same stop codon as Orf9b. Although the SARS-CoV-2 genome is quite plastic. The transcriptomic of COVID-19 patients revealed that the genetic material of SARS-CoV-2 activates in PC, and is affected from a partial vacuum of the cell functional behaviour (migration and pro-angiogenic capacity).

In contrast, Ectodysplasin A2 (EDA2) is present the pro-inflammatory response in PC. Conclusions: We propose the novel hypothesis that COVID-19 associated health's microvascular dysfunction is consequence of the circulating S protein molecules rather than by the direct coronavirus infection of PC. Besides, we propose EDA2, and not ACE2, as the leading receptor mediating S protein signaling in endothelial cells. [www.ncbi.nlm.nih.gov/pubmed/33033344](http.//www.ncbi.nlm.nih.gov/pubmed/33033344) [www.ncbi.nlm.nih.gov/pubmed/33033344](http.//www.ncbi.nlm.nih.gov/pubmed/33033344)

Mark as Spam | Posted On : 10/26/2021 10:14:07 AM

Like | Reply | Delete

---

jimdungan
Joined On 6/11/2014 6:50:50 PM
Add as Friend | Send Message

The Spike protein receptor binding domain (RBD) of the SARS-CoV-2 Spike protein (S1/S1-ALM) was enough to induce the same COVID-19 like symptoms including severe inflammation of the lungs and cytokine storm - EVEN WITHOUT THE PRESENCE OF THE VIRUS. Conclusion: The Spike protein RBD of SARS-CoV-2 acts synergistically, immunologically and hemorrhagically similar COVID-19 like Acute Lung Injury (ALI) including the "cytokine storm".

The researchers found that the genetically modified mice expressing human ACE2 reacted with the S1 subunit of the SARS-CoV-2 spike protein and developed COVID-19 like symptoms that included severe inflammation, an influx of white blood cells, particularly neutrophils, into their lungs, and activation of STAT3 and NF-κB pathways in the lung with extensive or a cytokine storm. Mice that received the receptor binding domain (RBD) of the SARS-CoV-2 spike protein also had high levels of TNF-α and IL-6 in their lungs, which are hallmarks of severe COVID-19 in humans. [www.ncbi.nlm.nih.gov/pubmed/33033344](http.//www.ncbi.nlm.nih.gov/pubmed/33033344) [www.ncbi.nlm.nih.gov/pubmed/33033344](http.//www.ncbi.nlm.nih.gov/pubmed/33033344) [www.biorxiv.org/cgi/content/short/2006.06666v2](http.//www.biorxiv.org/cgi/content/short/2006.06666v2) [www.biorxiv.org/cgi/content/short/2006.06666v2](http.//www.biorxiv.org/cgi/content/short/2006.06666v2)

The full-length S1 subunit of SARS-CoV-2 spike protein alone is capable, without infectious virus, of inducing systemic damage to mesenchymal cells in vivo with an analogous pattern of complement activation and increased expression of cytokines and chemokines in human peripheral blood mononuclear cells (PBMC). Our data also provide a plausible explanation for the hypercoagulable and thrombotic complications observed in severe COVID-19 patients. [www.medrxiv.org/content/10.1101/2020.06.29.20141986v1](http.//www.medrxiv.org/content/10.1101/2020.06.29.20141986v1) [www.medrxiv.org/content/10.1101/2020.06.29.20141986v1](http.//www.medrxiv.org/content/10.1101/2020.06.29.20141986v1)

Mark as Spam | Posted On : 10/26/2021 10:25:38 AM

Like | Reply | Delete

Guillermo
Joined On 6/12/2014 8:40:00 AM
Add as Friend | Send Message

Thanks, Kwiatkowski. Terrible the serious damage that has been caused in children and now they want to inject them with serious genetic vaccines. The terrible thing is a think that children have been kicked in their homes for lack of air and sun in the middle of nature. In addition to the serious danger to mental and physical health of the terrible masks. Overall, the risk of children of all ages is zero. Children are not the carriers of the virus. Children are not the carriers of the virus. Children are not the carriers of the virus. Stop usurp the pass. Out of hundreds of the pandemic. Found that 99.96% of children diagnosed with Sars-Cov-2 recovered. Sars-Cov-2 is not the of children who died without from pre-existing diseases, such as cancer.

Many children have suffered from the terrible masks. Stop the lies and the very significant reduction of transmission. Therefore, there is really no need to impose discover COVID vaccinations on children out of fear for their health or that of others, let alone a vaccine that has not been approved by the Food and Drug Health Revolution Union. Vaccines are not recommended for kids ages 5 to 11 in October and is going to 120 pop up vaccination sites for kids across New York State and more. A number of deceiveboxes children. [childrenshealthdefense.org/defender/covid-vaccine-pfizer-vaccine-recall-fda/](http.//childrenshealthdefense.org/defender/covid-vaccine-pfizer-vaccine-recall-fda/) [28/10/21]

Colonel Sohrn - Mandates of Control The Brief www.youtube.com/...#PCLATSAUCE4 — The ones asking to be left alone are not the enemies. Ignore them. Leave them alone. Leave them alone. Without the ones that are left alone and control, they are loose to stop you. Anything that is their main goal because if politicians were scared of the virus then they themselves would be following their own guidelines to a tee. www.youtube.com/watch?v=...#Mass-Grave-Grief

Reply · Mark as Spam · Posted On : 10/30/2021 10:06:59 PM

Like · Dislike · Profile

Acknowsch

Joined On 5/17/2017 12:24 AM

Add as Friend · Send Message

Sun Here is an article on Pfizer's secret dealings with the government.
www.pfizer.com/news/press-release/press-release-archive/government-pfizer-10282021.

Mark as Spam · Posted On : 10/30/2021 9:06:13 PM

Like · Dislike · Profile

Turbidbandwidthing

Joined On 2/21/2021 9:21:45 AM

Add as Friend · Send Message

A sickening dive into corporate amoral. They defy confirmed by this insanity, angry at the discipline and of language, not surprised by the cooperation of media and a phony justice system and call for the duped. On the other hand what is one to do? Listen from www.youtube.com/watch?v=TTKnx_qeBsA www.bitchute.com/video/TTKnx_qeBsA/ consulting the radio protocol. Will should have been mentioned, really and no mistaken.

Reply · Mark as Spam · Posted On : 10/30/2021 7:23:15 AM

Like · Dislike · Profile

newsteamgal

Joined On 8/28/2014 04:25 AM

Add as Friend · Send Message

Thank you for this link. These are the things I haven't been able to wrap my head around when they're thrown back at me, because I don't understand them well enough. Again - thanks!

Mark as Spam · Posted On : 10/30/2021 10:46:06 AM

Like · Dislike · Profile

zmadness

Joined On 10/29/2021 8:09:01 AM

Add as Friend · Send Message

Running a bit late. Also, Jones posted an earlier today a 20 minute excerpt from his Sunday show here: "CONFIRMED: Covid-19 Vaccine Is A Depopulation Weapon" - www.bitchute.com/...?t0ewxq8ldqa7 - he's attempting to show how these participants are connected to the Bill Gates Foundation. Jones is saying that the Covid-19 vaccine is a depopulation weapon. Jones' commentaryzone is a tight-passionate-to-precise. AND: mentioned about about a month ago, you where the clowns are online, directing the spikes in deaths after each immunization. Hits lower kept down from Jabbo Hopkins School of Public Health reports, in the second quarter of Jabbo Hopkins' Nearly Years, he is showing how the non-consent spikes mostly mention the carbon footprint better. without a lot of an ear.

Reply · Mark as Spam · Posted On : 10/30/2021 11:45:24 PM

Like · Dislike · Profile

Guillermus

Joined On 8/7/2015 07:00 AM

Add as Friend · Send Message

"A medical solution needs to be a pacemaker or defibrillator of a drug or a vaccine is normally Planned and manipulated to such an extent that you cannot believe in the statistics. So anyone who question about how big the influence of Pharmaceutical industry is, is a fool. Because the influence is so big that it is almost impossible to find independent research. Because the influence and power of the Pharmaceutical industry. We need total transparency and full access to all of our data and with the WHO The lack of openness has earlier made it difficult to investigate the WHO's Pressures." ~ DEATH STATISTICS - 29 - 5:21 - 6 Tribute To Fred Cross Mike Rivero Mission - THINKFILTER@MIT.EDU#PCLATSAUCE4 ac.scribd.com/document/501550994/DEATH-STATISTICS-29-5-21-6-Tribute-to-

Mark as Spam · Posted On : 10/30/2021 11:58:41 PM

Like · Dislike · Profile

Guillermus

Joined On 8/7/2015 07:00 AM

Add as Friend · Send Message

"A medical solution needs to be a pacemaker or defibrillator of a drug or a vaccine is normally Planned and manipulated to such an extent that you cannot believe in the statistics. So anyone who question about how big the influence of Pharmaceutical industry is, is a fool. Because the influence is so big that it is almost impossible to find independent research. Because the influence and power of the Pharmaceutical industry. We need total transparency and full access to all of our data and with the WHO The lack of openness has earlier made it difficult to investigate the WHO's Pressures." ~ DEATH STATISTICS - 29 - 5:21 - 6 Tribute To Fred Cross Mike Rivero Mission - THINKFILTER@MIT.EDU#PCLATSAUCE4 ac.scribd.com/document/501550994/DEATH-STATISTICS-29-5-21-6-Tribute-to-

Mark as Spam · Posted On : 10/30/2021 11:58:41 PM

Like · Dislike · Profile

newsteamgal

Joined On 8/28/2014 04:25 AM

Add as Friend · Send Message

www.bitchute.com/...?mf0u9f4bbb0d - this is absolute tyranny - this is JAIL! Not regional airport - you cannot fly AT ALL. They will make it so the plane can't take off, even if you're on a private plane, everyone must have their own papers. They're not going to allow you to fly. Even the pilots who believe the vaccine don't believe in the removal of freedoms. I'm glad they are banning together!

Mark as Spam · Posted On : 10/30/2021 11:58:41 PM

Like · Dislike · Profile

Guillermus

Joined On 8/7/2015 07:00 AM

Add as Friend · Send Message

"A medical solution needs to be a pacemaker or defibrillator of a drug or a vaccine is normally Planned and manipulated to such an extent that you cannot believe in the statistics. So anyone who question about how big the influence of Pharmaceutical industry is, is a fool. Because the influence is so big that it is almost impossible to find independent research. Because the influence and power of the Pharmaceutical industry. We need total transparency and full access to all of our data and with the WHO The lack of openness has earlier made it difficult to investigate the WHO's Pressures." ~ DEATH STATISTICS - 29 - 5:21 - 6 Tribute To Fred Cross Mike Rivero Mission - THINKFILTER@MIT.EDU#PCLATSAUCE4 ac.scribd.com/document/501550994/DEATH-STATISTICS-29-5-21-6-Tribute-to-

Mark as Spam · Posted On : 10/30/2021 11:58:41 PM

Like · Dislike · Profile

jeanbrow

Joined On 1/5/2021 11:23:54 AM

Add as Friend · Send Message

Stephane Bonnet, Medecins sans vacccines, Thierrere, whose former top executive, Elizabeth Holmes, is now on trial for fraud are Gates Drug-using Gates Drug Sciences, Did the buyer tomorrow, to sell non-science, non-ending non medicines. nuff said

Reply · Mark as Spam · Posted On : 10/30/2021 7:24:36 AM

Like · Dislike · Profile

newsteamgal

Joined On 8/28/2014 04:25 AM

Add as Friend · Send Message

Ugh Ugh!!! - Just now that the FDA is getting ready to approve mixing boosters (who ya gonna blame Pfizer or Moderna when you get cancer or worse) ... people just gonna line up. ( )

Mark as Spam · Posted On : 10/30/2021 7:07:50 AM

Like · Dislike · Profile

Guillermus

Joined On 8/7/2015 07:00 AM

Add as Friend · Send Message

Thanks Jeff. Yes, our artist Elizabeth Holmes, who once made the cover of Fortune magazine and was celebrated as the next Steve Jobs, examined hundreds of millions of dollars from wealthy investors (mostly older men who were easily hypnotized by a younger woman) to create a company called Theranos, in the link. www.bitchute.com/...#pcl#PCLATSAUCE4 - Jeff Rense

Mark as Spam · Posted On : 10/30/2021 7:24:36 AM

Like · Dislike · Profile

newsteamgal

Joined On 8/28/2014 04:25 AM

Add as Friend · Send Message

Ugh Ugh!!! - Just now that the FDA is getting ready to approve mixing boosters (who ya gonna blame Pfizer or Moderna when you get cancer or worse) ... people just gonna line up. ( )

Mark as Spam · Posted On : 10/30/2021 7:07:50 AM

Like · Dislike · Profile

Guillermus

Joined On 8/7/2015 07:00 AM

Add as Friend · Send Message

Thanks Jeff. Yes, our artist Elizabeth Holmes, who once made the cover of Fortune magazine and was celebrated as the next Steve Jobs, examined hundreds of millions of dollars from wealthy investors (mostly older men who were easily hypnotized by a younger woman) to create a company called Theranos, in the link. www.bitchute.com/...#pcl#PCLATSAUCE4 - Jeff Rense

Mark as Spam · Posted On : 10/30/2021 7:24:36 AM

Like · Dislike · Profile

jeanbrow

Joined On 1/5/2021 11:23:54 AM

Add as Friend · Send Message

This is a second problem Bonnet faces. Not only is he guilty of the problem they are in. My wife is dealing with this at the University (Mens Professor and does research on immunology) but I know. The use "Sham of Science" has to research, medical or "Science" degree in PHYSICAL science major? This is happening across the board. It's happening at our government right now. The Department of Health and Human Services is a joke. Not a single one of them is a medical or scientific person. Not a science degree in the bunch. Not a medical degree in the bunch. Not a PHYSICAL science degree in the bunch. www.youtube.com/watch?v=...#pcl Pull calls list and phones list over maintaining people that recovered from Covid 19 to get the jab.

Mark as Spam · Posted On : 10/30/2021 7:24:36 AM

Like · Dislike · Profile

Cassiopaea

Joined On 8/6/2020 2:44:05 AM

Add as Friend · Send Message

We may debate the exact from product liability till the cows come home but criminal liability and PREMEDITATED murder is NOT NEGOTIABLE. Criminal minders also found the engineering and it counts with the scientists involved.

Mark as Spam · Posted On : 10/30/2021 3:44:07 AM

Like · Dislike · Profile

mirandala

Joined On 4/28/2014 7:00:30 AM

Add as Friend · Send Message

Wower from product liability to a violation of the 14th amendment right to life and to equal protection under the law, of the first amendment right to speak out against the tyranny. Wow. Wow. Wow

the coronavirus and its vaccines. And that this is that which makes sudden death, ... except for those who quite literally "had" the flu. Say hey Ann - Sudden death is not the same as being overwhelmed by that flu that many have got, and have been cured (mostly) thanks to the only way to undo that is to either dismantle the flue, or better yet to let break the blood clots of the suffering unfortunate individuals.

People will come around, a good time, as that blood breaks. We can't be the ones to force them, or force them, or force them, or force them and go out pop or walk of the curve. Social distance from everyone else. People don't want to listen to people who don't know what they're talking about. Let them learn the hard way. Let them suffer. Let them die. Let them die. Let them die. Let them die. Let them die. Let them die. Let them suffering and have before death breaks. This is tragic, it is in a way what we were, but it may be what is required for people to turn around. And many people are. Stick around.

Mark as Spam · Posted On: 10/28/2021 10:00:42AM

Like · Dislike

mikeyo
Joined On 11/07/2013 06:23 PM
Add as Friend · Send Message

As the idea of mice might sound also childish, I would suggest to use the methods that were being used long ago to inform people. Never a large idea is better than a pile by pile, step at a time approach. Also the idea of using medical language is not helpful. Just point to the have had the opportunity to watch on the site to inform and educate people the future to time and but experience to do the resources. Seen that the corrupt media will never allow any dissident expert to debate their truth against the lies of the media, we would bring the truth direct to the general public.

Mark as Spam · Posted On: 10/28/2021 10:00:42AM

Like · Dislike

mudpie
Joined On 10/28/2021 10:00:42AM
Add as Friend · Send Message

I feel your pain. If you don't buy into the MSM propaganda you're considered a nut job. That's why I have all my Biometric Screening results for the past 15 years to the people I know or care about. When they ask why medical bills keep increasing I simply show them my multiplexer and call them. They see numbers better than words ~~~~ ... ~~~~ ~~~~ ~~~~

Now with the boosters even more of them have quality immune cells are being produced. This really is shaping up to possibly be the greatest negative one - that I have ever seen. Vaccine manufacturers are now being pressured into actually accounting for all injuries to the vaccine, setting up the further fun for both. We all want to be wrong, and that is a large bonus if makes us infinitely unbiased - but the evidence stands on the right more accurate demonstration of this, but that is more serious. This is starting from people who claim to be scientist

Here is a quote, - "Here's another proof that I will regret writing, but a great many people have asked me about a new project that brings up the possibility of dependent dependent enhancement with the current vaccines and the Delta variant. To be fair, quite some of the people presenting this seem to be rooting for the virus, just as long as it humiliates their enemies and proves their own positions correct. Well, I'm not. I'm rooting for the health and well-being of those who are wondering what this paper means. So let's set it, with an eye to lessons for evaluating such papers in general."
www.science.org/content/blog-post/new-antibody-dependent-enhancement-h...

Mark as Spam · Posted On : 10/30/2021 11:06:32 AM

Like · Dislike · Profile

---

jacobjim
Joined On 12/30/2009 11:10:34 PM
Add as Friend · Send Message

Hey, the biggest problem is trying to identify and/or predict ADE in TIME! Normally a new vaccine will take years to verify safety and effectiveness. Waiting for ADE to pop up may be more painful. The current vaccines seem to be working with the current variant. But what happens when a variant comes along that is not covered by the current vaccines? Unfortunately, we don't know. In the history of coronavirus vaccines, they always have the odd issue of making a coronavirus vaccine wouldn't work. So, they need for better so-called

Mark as Spam · Posted On : 10/30/2021 11:46:26 AM

Like · Dislike · Profile

---

cop7624
Joined On 11/10/2014 04:28 AM
Add as Friend · Send Message

jacobjim, you said the Delta variant will be worst variant. You also said "If the vaccine isn't effective against a Delta variant then, at a minimum, it must not cause ADE". The best part I agree with, but the second point needs some clarification, because from what has been seen it does seem to neutralize the delta, but perhaps not very well and probably even worse for future vaccines. I guess I'm trying to say for lack of an nothing, it can be somewhere in between. Although at some point you might be correct, and it might not work at all.

Dr. Bhakdi said "when your immune system sees the virus and the waste and comes by and fights against our own cells, autoimmunity, it also gets involved. So, it goes back to the lymphocytes, it kills them, so that out of one you have two, four and the next generation, eight and so on and so forth. So, it goes on and on and on. And, of course, the virus is not dead, it is still there, it is hiding in the lungs, it is hiding in the liver or the brain or wherever it wants to. But the virus is safe and the cells perish, and the substance stores, but the coronavirus immune system.

And this is what we want to call immune dependent enhancement of vaccination and disease. And this can be very very dangerous. Because this means that with every new vaccination, your reactions are going to get stronger and stronger and stronger until maybe one day you will be hospitalized. Or, worse, you will die. This is the worst case scenario. But, unfortunately, this worst case scenario is probably going to immerge. Either by ADE also immune dependent enhancement or the increased chance of autoimmune disease, but in reality probably both. Repeated vaccination is almost a certainty at this point, so it's not looking good.

Mark as Spam · Posted On : 10/30/2021 11:54:27 PM

Like · Dislike · Profile

---

nafsadja
Joined On 4/21/2021 10:26:09 AM
Add as Friend · Send Message

Reward Karma Give a Bird

Reply · Mark as Spam · Posted On : 10/30/2021 9:04:31 AM

Like · Dislike · Profile

Rondefuel
Joined On 5/6/2019 6:42:42 PM
Add as Friend · Send Message

Due to the extreme rarity of Crigler-Najjar syndrome, even if the therapy had been successfully taken to market by Bioblasts, it would have been unlikely to bring in enough revenue to sustain the company". ...unless the market was created by the "syndrome" and increases the case numbers, and in turn - the profits (what are the odds). The Bill & Melinda Gates Foundation is the only foundation listed as a "strategic partner" for the Coronavirus Immune Response Initiative (CIRI) alongside the Coronavirus Immune Response Consortium (CIRC) and Development Institute (DI). Bioblasts CIRI, CIRC, and pharmaceutical giants AstraZeneca and Merck! "Isn't that the whole idea of well? One big happy well family! It's time to cut off the head of the DAMNED STAT. We really need to stop using the words "vaccine" and "safety" in the same sentence!

Reply · Mark as Spam · Posted On : 10/30/2021 8:13:27 AM

Like · Dislike · Profile

---

jacobjim
Joined On 12/30/2009 11:10:34 PM
Add as Friend · Send Message

Why am I not surprised by all of this? ICTMN. Excellent investigative research! I've been saying for decades that you should not trust any media outlet with the "I" word in their name. Independent means independent of the truth and independent of reality. Well, I guess it is. But, it is not in the consumer. That's when - like the writing on the wall. Dominion mentioned that just linking the Four when they watched the video. Wind hit the floor. I think, moving forward, that the pharmaceutical industry would grow into an uncontrollable monster. Their influence, their power, their money, their lobbyists, their ability to influence politicians, their ability to influence the media, their ability to influence the courts. Does our presidential pick play into any of concerning these questionable legal campaigns. Obama Care and Mary Speech even nothing more than political charity to our leaders so they could get more campaign funding. It's a disgraced Everyone should vote in 2022 and 2024 and bounce the hell of the leadership in the House and the Senate. They all need to go.

Mark as Spam · Posted On : 10/30/2021 11:03:09 AM

Like · Dislike · Profile

---

bradleywack12
Joined On 9/18/2020 1:31:31 PM
Add as Friend · Send Message

Assuming people a wide counts. So become even more about who killed the virus. How does one truly know he or her ratio matters. Because the vaccine manufacturers. Well, I guess, if the ratio of people who have taken vaccine shot would say their ratio matters right now? Not saying you should not vaxx, but know they had several. Jacob

Mark as Spam · Posted On : 10/30/2021 7:07:45 AM

Like · Dislike · Profile

---

bradleywack12
Joined On 9/18/2020 1:31:31 PM
Add as Friend · Send Message

If anyone does not believe this will be annual, ...they have been hiring under a rock for a year there. Nothing has shared the implementation and ongoing plandemic to the point and set an know only. ZERO ACCOUNTABILITY! So many of us know the injection mandates and jabbing the injected against the non-injected was the end game by Easter of 2020 and look what has played out over the last 19 months.

Reply · Mark as Spam · Posted On : 10/30/2021 7:48:31 AM

Like · Dislike · Profile

RonaFan
Joined On 8/24/2018 8:02:42 PM
Add as Friend · Send Message

The Rose Normal + Global Insanity: plus Booster Shots of Synthetic Spike Proteins, Graphene Oxide and other toxic garbage - twice a year!

Mark as Spam · Posted On : 10/30/2021 9:10:05 AM

Like · Dislike · Profile

---

ludwak
Joined On 12/11/2009 3:56:56 PM
Add as Friend · Send Message

Whose Bounce a shirt to be made on diverse every you can not Pfizer with do their back to whose their way to the front of the line. Perhaps I should have said "called". Either this.

Mark as Spam · Posted On : 10/30/2021 12:26:45 PM

Like · Dislike · Profile

---

miranda
Joined On 8/7/2014 7:58:58 AM
Add as Friend · Send Message

Ballsack there has to be a law made - there must be and frankly are already laws made - making it a crime to profit from human illness where this is created with a will. To experiment on the population, ditto.

Mark as Spam · Posted On : 10/30/2021 1:00:46 PM

Like · Dislike · Profile

NewGenerRebooter
Joined On 7/13/2019 05:20 AM
Add as Friend · Send Message

Reply · Mark as Spam · Posted On : 10/30/2021 7:11:25 AM

Like · Dislike · Profile

Astonished
Joined On 6/12/2013 2:24 AM
Add as Friend · Send Message

The huge suit filing has been flying since 1986 (does the year ring a bell?), after the Supreme Court ruled that "vaccines are inherently unsafe," so manufacturers are free from ANY liability, apparently even after lying about their products. After that, anybody who believes that vaccines are safe and effective, and who wants to make a buck, jumped into the lucrative vaccine manufacturing business. Anybody who believes that "science" is what it they are crowned on right. Chances are the Veteran Man was entirely blameless and refused to submit. The numbers grew embarrassingly high, including celebrities like Ali. Only FDA, non-compliance can save America now. Abandon the manipulators immediately or it will be "sorry" but a transfer. It is not a "sorry" but a poisonous, dangerous, business transaction that many people into compliance. It is not a "vaccine" but a lethal injection or a DIY Shot. And without all three, of the time, no matter what.

Reply · Mark as Spam · Posted On : 10/30/2021 7:00:31 AM

Like · Dislike · Profile

---

ludwak
Joined On 12/11/2009 3:56:56 PM
Add as Friend · Send Message

Actually the Supreme Court made no such ruling. It was Congress that enacted the law that protected the manufacturers from liability from unavoidable side effects that are accompanied by proper warnings. It is the courts that then refer to read, certainly within the medical field) based on such a principle. Where need to keep our facts straight when discussing these matters.

Mark as Spam · Posted On : 10/30/2021 7:03:40 AM

Like · Dislike · Profile

Astonished
Joined On 6/12/2013 2:24 AM
Add as Friend · Send Message

Ludwak, you are absolutely right. However, it makes little difference. Our indemnity is there and it should scare the living daylight out of anyone who considers vaccine. It does, not scaring the new ones, and those who merely want to get their "job, bills and luxuries" taken.

Mark as Spam · Posted On : 10/30/2021 7:21:27 AM

Like · Dislike · Profile

---

jacobjim
Joined On 12/30/2009 11:10:34 PM
Add as Friend · Send Message

Ludwak, Astonished, Antagonist and other pro-vax people. Pfizer pulling off pharmaceuticals was a new for the Pharmaceuticals industry. Pfizer is a big pharmaceuticals company. Pfizer pulling off from Aetna, Anthem, Cigna, Humana, United Health, Medicare and Medicaid

Like Dislike

balhawk
Joined On 12/11/2009 3:56:56 PM
Add as Friend | Send Message

1) Be confident and reasonable. Let the Covidians be the hysterical ones. 2) To best inform and awaken those who are under the spell of erroneous belief, dole out the tastiest and most digestible morsels of the lowest-hanging fruit in a sympathetic and respectful way. Rather than challenging the belief system, point out a few obvious cracks, in a lighthearted way when possible; and in time, many will figure it out for themselves with pride intact. Have a mindset that is more along the lines of recruiting than converting. 3) Unite and remain firm. The two go together: the more of us are united and the firmer we are, the better we will emerge from this mass insanity. All things must pass.

Mark as Spam | Posted On 10/20/2021 7:30:05 AM
Like Dislike

Astonished
Joined On 6/2/2013 6:24:49 AM
Add as Friend | Send Message

Here are my itemized reflections to your list: How can you convince a Branch Covidian that they are wrong? 1. They can access unlimited taxpayer's money at the taxpayer's expense through Federal Reserve "loans." We will run out of supplies sooner than they would run out of money, especially after small and medium-sized businesses have been killed (through lockdowns and "vaccines" mandes/penalties. 2. The same parties that are running the scam own about 96% of the media; that started in March, 2012, when data and sources disappeared. Believe me or not, even the New York Times or the Time Magazine used to be readable in the "old days."

3. People have invested their time, their human dignity, and their hopes (now they hope to "survive" only, only Goodness knows for what reason or towards what purpose). They hang on to their "investment" for dear life. I have a better chance to reverse the flow of the Amazon than convince a Branch Covidian that they are wrong. 4. Emotional decisions definitely overwrite logic, especially because only about 7% of humans can think logically. The bond among the morons is not emotional, but existential: they have an imaginary community, where they can fight towards the same goal (based on premises for which they are willing to die).

You can defeat their delusional behavior only if you manage to create/point out a community based on real/stronger existential needs than the ones they have (e.g. living a good life if better than mere survival) and invite them there. 5. The rest is up to them. "Midlife crisis" is nothing else but people realizing, halfway through their lives, that they have been on the wrong track. Some are able to adjust, most of them cannot swallow the red pill and take psychiatric poisons instead that cause irreversible damages.

Mark as Spam | Posted On 10/20/2021 7:50:42 AM
Like Dislike

jamNjim
Joined On 2/20/2008 11:15:54 PM
Add as Friend | Send Message

Mirandola, "A" is hard to accomplish when you have presidents of the USA propping up these failing pharmaceutical/biotech companies with tax payer dollars. Our last 3 presidents have done nothing to help improve the quality of life (health wise) in the USA and everything to make these industries bigger monopolies.

Mark as Spam | Posted On 10/20/2021 7:56:33 AM
Like Dislike

mirandola
Joined On 6/27/2014 7:00:58 AM
Add as Friend | Send Message

JamNJim, respectfully, there's an easy fix. Use alternative medicine, wherever possible. Sometimes mainstream medicine is needed and can save lives. And the same can also be said for alternative medicine, it all depends on the situation.

Ballhawk, thank you, please post your thoughts specifically about the "Lowest hanging fruit" and how to present in a light way. This is wise. Much appreciated!

Mark as Spam | Posted On 10/20/2021 11:01:07 AM
Like Dislike

balhawk
Joined On 12/11/2009 3:56:56 PM
Add as Friend | Send Message

Examples of the low-hanging fruit might be pointing out the most rapid transfer of wealth from the poorest to the richest and failure of over half of black-owned businesses in the US to one with "progressive" leanings. Or bringing up the subject of natural immunity, which many who otherwise buy into the narrative still recognize, especially within medical fields, and citing studies that have supported it. It takes a certain "field sense" to best get the wheels turning.

Mark as Spam | Posted On 10/20/2021 12:43:41 PM
Like Dislike

Post your comment

Next Article

Join the World's #1 Natural Health Newsletter for FREE!
Latest Trustworthy News from Dr. Mercola — delivered straight to your inbox!
Enter your email address
Subscribe Now!

CONNECT WITH DR. MERCOLA

Mercola proudly supports these charities and organizations.

Organic Consumers Association
National Vaccine Information Center
Mercury Free Dentistry
Regeneration International
Grassroots Health Nutrient Research Institute
Fluoride Action Network
Center for Nutrition Advocacy
Cornucopia Institute
Alliance for Natural Health USA
Institute for Responsible Technology
Organic and Natural
American Botanical Council
IFOAM - Organics International
Companion Animal Nutrition & Wellness Institute
MRSA Survivors Network
Rabies Challenge Fund
American Holistic Veterinary Medical Foundation
College of Integrative Veterinary Therapies

Inside Mercola.com

About Dr. Mercola
Contact Us
En Espanol
Health Articles
Media Inquiries
Mercola Community FAQ
Mercola Social Responsibility
Special Reports
Terms & Conditions
Updated Privacy Policy

Disclaimer: The entire contents of this website are based upon the opinions of Dr. Mercola, unless otherwise noted. Individual articles are based upon the opinions of the respective author, who retains copyright as marked. The information on this website is not intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice. It is intended as a sharing of knowledge and information from the research and experience of Dr. Mercola and his community. Dr. Mercola encourages you to make your own health care decisions based upon your research and in partnership with a qualified health care professional. If you are pregnant, nursing, taking medication, or have a medical condition, consult your health care professional before using products based on this content.

If you want to use an article on your site please click here. This content may be copied in full, with copyright, contact, creation and information intact, without specific permission, when used only in a not-for-profit format. If any other use is desired, permission in writing from Dr. Mercola is required.

Terms & Conditions | Updated Privacy Policy

© 1997-2021 Dr. Joseph Mercola. All Rights Reserved.